LifeMD rises after adding new daily obesity pill to weight management program

LifeMD

10/04/2026 13:45

** Shares of telehealth firm LifeMD LFMD.O rise 3% to $3.48 premarket

** Co says it will offer Foundayo, a new once-daily oral pill for obesity, through its weight management program following U.S. FDA approval on April 1

** Says Foundayo, developed by Eli Lilly LLY.N, is for adults who are obese or overweight with related health issues

** Adds pricing starts at $149 a month for cash-paying patients; some commercially insured patients may pay as little as $25 using a Lilly savings card

** Says Medicare coverage is expected to begin in July; prescriptions to be filled via LillyDirect shipping to patients

** As of last close, stock down marginally YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))